Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation?

Liver Transplantation

Volumn 7, Issue 12, 2001, Pages 1009-1014

  Neal, David A J ^a   Alexander, Graeme J M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYCLOSPORIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PRAVASTATIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS;

ACUTE DISEASE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENERAL PRACTICE; GRAFT REJECTION; HEART GRAFT; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; T LYMPHOCYTE; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

EID: 0035660020     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2001.27476     Document Type: Article

References (89)

1. Progress in posttransplant hyperlipidemia
2. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation
3. Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)
4. Hyperlipidaemia and obesity after orthotopic liver transplantation
5. Long-term medical complications in patients surviving > 5 years after liver transplant
6. Metabolic complications after liver transplantation
7. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506
8. Hyperlipidemia in liver transplant recipients: Prevalence and risk factors
9. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy
10. The effect of FK506 versus cyclosporine on glucose and lipid metabolism-A randomized trial
11. Hyperlipidaemia after liver transplantation: Long-term results of the American FK506/cyclosporine US multicenter trial
12. Serum lipid abnormalities in pediatric liver transplant patients
13. Hyperlipidaemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
14. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation
15. Hyperlipidaemia in renal transplant recipients: Natural history and response to treatment
16. Hyperlipidemia and other coronary risk factors after orthotopic liver transplantation: Pathogenesis, diagnosis, and management
17. Cyclosporine, low density lipoprotein, and cholesterol
18. Effects of cyclosporine A on LDL receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in the rat
19. Influence of long-term cyclosporine or FK506 therapy on glucose and lipid metabolism in stable liver graft recipients
20. Sirolimus (rapamycin)-based therapy in human renal transplantation
21. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper)
22. Prednisolone withdrawal late after liver transplantation reduces diabetes, hypertension, hypercholesterolaemia without causing graft loss
23. Cardiovascular disease after renal transplantation
24. Transplant coronary disease: Nonimmunologic risk factors
25. Lipid disorder and transplant coronary artery disease in long-term survivors of heart transplantation
26. Lipids, lipoprotein(a) and coronary artery disease in patients following cardiac transplantation
27. Hyperlipoproteinaemia in renal transplant recipients: Is there a linkage with chronic vascular rejection?
28. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation
29. Risk factors predicting chronic rejection of renal allografts
30. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients
31. Ten years of liver transplantation
32. Cardiovascular complications following liver transplantation
33. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation
34. Low dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation
35. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients
36. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine
37. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolaemic renal transplant patients
38. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine
39. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients
40. Low-dose simvastatin is a well tolerated and efficacious cholesterol-lowering agent in cyclosporine-treated kidney transplant recipients: Double-blind, randomised placebo-controlled study in 40 patients
41. The effects of pravastatin on hyperlipidaemia in renal transplant recipients
42. Abnormal lipoprotein(a) and lipid profiles in renal allograft recipients: Effects of treatment with pravastatin
43. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolaemia in renal transplant patients receiving cyclosporine
44. The efficacy and safety of fluvastatin in hypercholesterolaemia in renal transplant recipients
45. Hyperlipidaemia after liver transplantation: Natural history and treatment with the hydroxy-methylglutaryl-coenzyme A reductase inhibitor pravastatin
46. Short-term effects of statin therapy in patients with hyperlipoproteinaemia after liver transplantation: Results of a randomized cross-over trial
47. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
48. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
49. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
50. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
51. Joint British recommendations on prevention of coronary heart disease in clinical practice
52. Consensus conference on lipid lowering to prevent vascular events
53. Lipids and the primary prevention of coronary heart disease
54. Secondary prevention of coronary heart disease following myocardial infarction
55. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
56. Identifying patients at risk for coronary heart disease: Implications from trials of lipid-lowering drug therapy
57. A comparison of methods for targeting CHD risk for primary prevention
58. 1996 National Heart Foundation guidelines for the assessment and management of dyslipidaemia
59. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
60. Effect of pravastatin on outcomes after cardiac transplantation
61. The effect of pravastatin on acute rejection after kidney transplantation; A pilot study
62. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomised trial
63. Natural killer cells in renal allograft rejection
64. Increase in natural killer cell activity in cyclosporine-treated renal allograft recipients during rejection
65. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl enzyme A reductase by lovastatin
66. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity
67. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin 2
68. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro
69. The vascular pathology of human hepatic allografts
70. Allograft vascular disease: Comparison of heart and other grafted organs
71. Chronic liver allograft rejection and obliterative arteriopathy: Possible pathogenic mechanisms
72. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
73. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages
74. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages
75. HMG-CoA reductase inhibitors: In vivo effects on carotid intimal thickening in normochoesterolaemic rabbits
76. Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes
77. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types
78. Lipids and endothelial functions: Effects of lipid-lowering and other therapeutic interventions
79. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
80. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors
81. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischaemia and Function of the Endothelium) trial
82. Value of endothelin in cellular rejection after liver transplantation
83. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelin nitric oxide synthase in vascular endothelial cells
84. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolaemia
85. Hyperlipidaemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
86. Statins as a newly recognised type of immunomodulator
87. Stimulation of bone formation in vitro and in rodents by statins
88. Lovastatin decreases mortality and improves liver function in fulminant hepatic failure from 90% partial hepatectomy in rats